Clinical trials: Transplant
Steroid Refractory Acute Graft Versus Host Disease
Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease
This is a single-arm, open-label, multicenter study of the efficacy of UVADEX® (methoxsalen) Sterile Solution in conjunction with THERAKOS® CELLEX® Photopheresis Systems (ECP) in pediatric participants with steroid-refractory…
- Trial name
- NCT02524847
- Testing
- Methoxsalen, Extracorporeal Photopheresis (ECP)
- Where
- 32 sites in United States, Austria and 6 more
- Volunteers
- 29 people
- Sponsor
- Therakos, Inc., a Mallinckrodt Company
Heart Transplantation
Quantification of Intramyocardial Lipid by Proton Magnetic Resonance Spectroscopy
Accumulation of triglycerides in heart tissue has been associated with changes in left ventricular function which can lead to heart failure.
- Trial name
- MRS (NCT00469911)
- Testing
- Magnetic Resonance Spectroscopy, Ex vivo heart biopsy
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Infections After Lung Transplant
Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement
Immunosuppressive therapies have led to remarkable improvements in survival in lung transplantation (LT) patients. However, one important adverse effect of these therapies has been the increasing emergence of…
- Trial name
- NCT01361178
- Testing
- SQ IVIG
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- University of Pittsburgh
Pulmonary Arterial Hypertension
Nitric Oxide, GeNO Nitrosyl Delivery System
The primary aim of the study is to evaluate the safety, tolerability and device performance of the GeNO nitrosyl delivery system during RHC.
- Trial name
- NCT01165047
- Testing
- Nitric Oxide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Acute Myelogenous Leukemia, Acute Lymphoid Leukemia
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
The goal of this study is to determine whether post-transplant consolidation with azacitidine combined with donor lymphocyte infusion (DLI) is a safe and effective approach for the prevention of relapse in pediatric and young…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02458235
- Testing
- azacitidine, donor lymphocyte infusion
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Hematologic Malignancies
Stem Cell Transplant for Hematologic Diseases
Patients are being asked to participate in this study because they have a cancer in their blood, Fanconi's Anemia, or have been unsuccessfully treated for bone marrow failure such as Aplastic Anemia or Paroxysmal Nocturnal…
- Trial name
- HIMSUM (NCT00058825)
- Testing
- Campath 1H, Fludarabine, Stem Cell Transplant
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine
Myeloma, Plasma-Cell, Myeloma-Multiple
Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma
Background: Cancer development is associated with problems in immune system functions, which prevent the body from attacking and destroying the abnormal cells that lead to tumor growth.
- Conditions
- Myeloma, Plasma-Cell, Myeloma-Multiple, Myelomatosis
- Trial name
- NCT01239368
- Testing
- Adoptive Immunotherapy, Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells), Th1/Tc1 Rapa Cell Therapy
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant
This phase II trial studies how well lenalidomide works in treating patients with progressive or recurrent multiple myeloma after a donor stem cell transplant.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00619684
- Testing
- lenalidomide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment
TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
In this phase I trial, patients with relapsed or refractory multiple myeloma will receive standard autologous stem cell transplant conditioned with high dose melphalan.
- Trial name
- BMT-03 (NCT02043847)
- Testing
- Total Marrow Irradiation, Melphalan, Filgrastim (G-CSF)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Illinois Chicago
Kidney Transplantation
Bela 8 Week Dosing
The purpose of this study is to transition patients who have been stable on Belatacept for one year after kidney transplant from standard 4-week to an investigational 8-week belatacept dosing schedule.
- Trial name
- NCT02560558
- Testing
- Belatacept
- Where
- 2 sites in United States
- Volunteers
- 166 people
- Sponsor
- Emory University
Multiple Myeloma
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
This study is for patients that have multiple myeloma that has come back or relapsed and their condition indicates a procedure called an Autologous Hematopoietic Stem Cell Transplantation (AHSCT).
- Trial name
- NCT01690143
- Testing
- Carfilzomib, Melphalan
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Alabama at Birmingham
Multiple Myeloma, Autologous Stem Cell Transplant
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo, in participants with newly diagnosed multiple myeloma (NDMM) who have had a…
- Trial name
- NCT02181413
- Testing
- Ixazomib Citrate
- Where
- 227 sites in United States, Argentina and 31 more
- Volunteers
- 656 people
- Sponsor
- Takeda
Disorder Related to Renal Transplantation
A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
The purpose of this clinical research study is to learn if belatacept (BMS-224818) is expected to show acceptable rates of acute rejection (AR) in steroid-free belatacept-based immunosuppressive regiments compared to a similar…
- Trial name
- NCT00455013
- Testing
- Thymoglobulin, Belatacept, Sirolimus
- Where
- 17 sites in United States, Italy and 1 more
- Volunteers
- 93 people
- Sponsor
- Bristol-Myers Squibb
BK Virus (Nephropathy)
Cidofovir in Renal Transplant Recipients With BKVN
This study will look at the safety, tolerability and effectiveness of cidofovir in kidney transplant patients who have been diagnosed with BK virus nephropathy (BKVN), a viral condition that can cause patients to reject…
- Trial name
- NCT00138424
- Testing
- Cidofovir
- Where
- 12 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00096161
- Testing
- Cyclosporine, Mycophenolate Mofetil, Pentostatin
- Where
- 5 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent Clostridium Difficile Infection
Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection
This is a randomized, open label, comparative, Phase II study to determine which dose of fecal microbiota transplant using Penn Microbiome Therapy (PMT) products is most effective in treating and preventing recurrence of…
- Trial name
- NCT03973697
- Testing
- Penn Microbiome Therapy - 001, Penn Microbiome Therapy - 002, Penn Microbiome Therapy - 003
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pennsylvania
Liver Transplant Recipient
Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients
The reason for this extension is to evaluate the long-term safety and efficacy of two concentration-controlled everolimus regimen in de novo liver transplant recipients.
- Trial name
- NCT01150097
- Testing
- Tacrolimus (reduced tacrolimus), Everolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination)
- Where
- 57 sites in United States, Argentina and 14 more
- Volunteers
- 284 people
- Sponsor
- Novartis Pharmaceuticals
Tear of Meniscus of Knee
Clinical Application of BioCleanse Meniscus
This study will follow patients after routine surgery of a meniscal allograft transplant.
- Trial name
- Meniscus (NCT00659880)
- Testing
- BioCleanse Meniscus
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- RTI Surgical
Kidney Transplant Recipient
Subcutaneous Abatacept in Renal Transplant Recipients
After a kidney transplant, patients take drugs called anti-rejection drugs (immunosuppressives) to prevent their bodies from rejecting the new kidney.
- Trial name
- RTB-016 (NCT05975450)
- Testing
- Abatacept 125Mg/Ml Syringe
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Idelberto Badell
Kidney Transplantation
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
To investigate the safety and tolerability of treatment with low dose rIL-2 in renal transplant recipients. To assess the immunologic impact of low dose rIL-2 in renal transplant recipients.
- Trial name
- NCT02417870
- Testing
- aldesleukin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Anil K. Chandraker, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.